- Home
- HEPS vs APMD Comparison
HEPS vs APMD Comparison
Compare HEPS & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | APMD |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 895.5M |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HEPS | APMD |
|---|---|---|
| Price | $2.78 | $18.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.31 | ★ $50.33 |
| AVG Volume (30 Days) | 209.3K | ★ 380.6K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.24 | $136.17 |
| Revenue Next Year | $29.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $16.43 |
| 52 Week High | $3.30 | $35.29 |
Technical Indicators
Market Signals| Indicator | HEPS | APMD |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 43.61 |
| Support Level | $2.74 | N/A |
| Resistance Level | $2.78 | $30.22 |
| Average True Range (ATR) | 0.08 | 1.64 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 92.11 | 45.47 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. It's portfolio offers its retail customers a wide selection of merchandise including electronics and non-electronics (including books, sports, toys, kids and baby products, cosmetics, furniture, etc). The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).